Autres langues Lisata Therapeutics, Inc.

Actions

LSTA

US1280583022

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 30/04/2024			Varia. 5j.	Varia. 1 janv.
2,73 ^USD	-0,73%		+3,02%	-.--%

23/04	Lisata Therapeutics, Inc et Qilu Pharmaceutical Co, Ltd annoncent le premier patient traité dans l'essai de phase 2 de Qilu en Chine sur LSTA1 chez des patients atteints d'adénocarcinome canalaire pancréatique métastatique	CI
17/04	Lisata Therapeutics, Inc. nomme James Nisco au poste de Senior Vice President, Finance and Treasury and Chief Accounting Officer.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	24/04
Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors	23/04
Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer	23/04
Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc and Qilu Pharmaceutical Co., Ltd Announce First Patient Treated in Qilu?s Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma	23/04
Lisata Therapeutics, Inc. Appoints James Nisco as Senior Vice President, Finance and Treasury and Chief Accounting Officer	17/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma	09/04
Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events	03/04
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	21/03
Sector Update: Health Care Stocks Higher in Afternoon Trading	21/03
Lisata Therapeutics Says FDA Grants Rare Pediatric Disease Designation to Osteosarcoma Drug	21/03
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma	21/03
Lisata Therapeutics to Present at the Life Science Investor Forum on March 7ᵗʰ	04/03
Lisata Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update	29/02
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22/02
Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time	22/02
Lisata Therapeutics to Present at BIO CEO & Investor Conference	20/02
Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico	18/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lisata Therapeutics, Inc.

Actions

LSTA

US1280583022

Autres langues

Filtres